INOVIQ Ltd (FRA:EGQ0)

Market Cap	29.42M -14.1%
Revenue (ttm)	1.01M +16.3%
Net Income	-3.87M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	0.1970
Previous Close	0.1950
Day's Range	0.1970 - 0.1970
52-Week Range	0.1610 - 0.3060
Beta	n/a
RSI	47.07
Earnings Date	Feb 18, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of can...

• Industry: Gold And Silver Ores
• Founded: 2016
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EGQ0

Financial Performance

In fiscal year 2025, INOVIQ's revenue was 1.82 million, an increase of 16.25% compared to the previous year's 1.56 million. Losses were -6.93 million, 5.77% more than in 2024.

Financial numbers in AUD